vimarsana.com
Home
Live Updates
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis : comparemela.com
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis
SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative
Related Keywords
Macau ,
China ,
South Korea ,
Shanghai ,
Singapore ,
Vijay Karwal ,
Ocular Therapeutix Inc ,
Nasdaq ,
Singapore Health Sciences Authority ,
Affamed Therapeutics ,
New Drug Application ,
Chief Executive Officer ,
Mainland China ,
Ocular Therapeutix ,
Greater China ,
Amed Therapeutics ,
comparemela.com © 2020. All Rights Reserved.